The reorganization of the dialysis specialist Fresenius Medical Care $FME (+0,58 %) is finally taking effect! 🚀 Last year, the company, which is listed on the DAX, significantly increased its operating result and also surprised with a higher dividend. Group CEO Helen Giza has focused on cutting costs in order to keep the company on track.
Fresenius Medical Care performed better than expected, particularly in the final quarter. By 2025, Giza plans to permanently reduce costs by 750 million euros - an increase of 100 million euros on the original target. This shows that the strategic reorganization is bearing fruit and efficiency has been increased.
Fresenius Medical Care shares initially rose by 4 percent before giving up some of their gains. Analyst David Adlington of J.P. Morgan described the quarterly figures as unexpectedly strong. The outlook for the operating result for 2025 leaves room for positive surprises.
Shareholders can therefore look forward to a substantial dividend increase and an exciting future for Fresenius Medical Care!